

SEED**Intellectual Property Law Group PLLC**

701 Fifth Avenue, Suite 6300
Seattle WA 98104-7092 USA
Facsimile: (206) 682-6031
Telephone: (206) 622-4900
www.seedlaw.com

October 3, 2003

Julie A. Urvater, Ph.D., Patent Agent
Direct Line: (206) 694-4877
julieu@seedlaw.com

Facsimile Transmission**7** pages including this page

TO: EXAMINER: Delia M. Ramirez
ART UNIT: 1652
Fax No.: (703) 308-0294

RE: U.S. Patent Application No. 10/153,510
10/053,510
Attorney Docket No.: 200116.402C2

Urgent **For Review** **Please Confirm Receipt** **Please Reply ASAP**

Comments:

Please find attached a copy of the Response to Restriction Requirement and Preliminary Amendment, along with return postcard, that was filed March 25, 2003.

PLEASE DELIVER IMMEDIATELY

TO

EXAMINER: Delia M. Ramirez


ART UNIT: 1652

If you do not receive all pages, please call Tiffany Tarleton at (206) 622-4900 or fax our office.

Transmission Information: Date _____ Time _____ By _____

CONFIDENTIALITY NOTICE: The information contained in this facsimile message is legally privileged and/or confidential information intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any use, dissemination, distribution, or copying of this facsimile or its content is strictly prohibited. If you have received this facsimile in error, please immediately notify us by telephone and return the original facsimile message to us by mail or destroy it without making a copy. Thank you.

Express Mail No. EV207704968US

200116.402C2
JAU:tt
*JD/***Box Non-Fee Amendment**
Commissioner for Patents
Washington, DC 20231SENT: March 25, 2003
DUE: March 25, 2003Date StampKindly acknowledge receipt of the below-listed documents by placing
your receiving stamp hereon and mailing:

**PTO/SB/21; Response to Restriction Requirement and Preliminary Amendment; in
re: Julie D. Saba et al., USAN 10/053,510, filed January 17, 2002, for
SPHINGOSINE-1-PHOSPHATE LYASE POLYPEPTIDES,
POLYNUCLEOTIDES AND MODULATING AGENTS AND METHODS OF USE
THEREFOR.**

368422_1.DOC

SEED INTELLECTUAL PROPERTY LAW GROUP PLLC

EXPRESS MAIL NO. EV207704968US
PTO/SB/21 (08-00)Please type a plus sign (+) inside this box →

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


**TRANSMITTAL
FORM**(To be used for all correspondence
after initial filing)

Application Number	10/053,510
Filing Date	January 17, 2002
First Named Inventor	Julie D. Saba
Group Art Unit	1652
Examiner Name	Delia M. Ramirez
Attorney Docket No.	200116.402C2

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> CD(s), Number of CD(s) _____
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input checked="" type="checkbox"/> Amendment/Response	<input type="checkbox"/> Request for Corrected Filing Receipt	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> After Final	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address	<input checked="" type="checkbox"/> Return Receipt Postcard
<input type="checkbox"/> Information Disclosure Statement; Form PTO-1449	<input type="checkbox"/> Declaration	<input type="checkbox"/> Additional Enclosure(s) (please identify below): _____ _____ _____
<input type="checkbox"/> Cited References	<input type="checkbox"/> Statement under 37 CFR 3.73(b)	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Request for Refund	

Remarks**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Individual Name	Julie A. Urvater, Ph.D., Patent Agent Reg. No. 50,461	 00500 PATENT TRADEMARK OFFICE
Signature		
Date	March 25, 2003	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.

Typed or printed name		
Signature		Date:

EXPRS MAIL NO. EV207704968US

PATENT

8A
DR
10/15/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Julie D. Saba et al. 10/15/03
Application No. : 10/053,510
Filed : January 17, 2002
For : SPHINGOSINE-1-PHOSPHATE LYASE POLYPEPTIDES,
POLYNUCLEOTIDES AND MODULATING AGENTS AND
METHODS OF USE THEREFOR

Examiner : Delia M. Ramirez
Art Unit : 1652
Docket No. : 200116.402C2
Date : March 25, 2003

Box Non-Fee Amendment
Commissioner for Patents
Washington, DC 20231

RESPONSE TO RESTRICTION REQUIREMENT AND PRELIMINARY AMENDMENT

Commissioner for Patents:

In response to the Restriction Requirement dated February 25, 2003, Applicants hereby elect Group II, claims 4-6, directed to a method for identifying an agent that modulates sphingosine-1-phosphate lyase activity.

Prior to examination on the merits, please amend the application as follows:

Amendments to the claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 4 of this paper.